248 related articles for article (PubMed ID: 31269310)
1. Effects of P-gp and Bcrp as brain efflux transporters on the uptake of [
Jung KH; Oh SJ; Kang KJ; Han SJ; Nam KR; Park JA; Lee KC; Lee YJ; Choi JY
Synapse; 2019 Nov; 73(11):e22123. PubMed ID: 31269310
[TBL] [Abstract][Full Text] [Related]
2. (R)-[(11)C]verapamil is selectively transported by murine and human P-glycoprotein at the blood-brain barrier, and not by MRP1 and BCRP.
Römermann K; Wanek T; Bankstahl M; Bankstahl JP; Fedrowitz M; Müller M; Löscher W; Kuntner C; Langer O
Nucl Med Biol; 2013 Oct; 40(7):873-8. PubMed ID: 23845421
[TBL] [Abstract][Full Text] [Related]
3. Tariquidar and elacridar are dose-dependently transported by P-glycoprotein and Bcrp at the blood-brain barrier: a small-animal positron emission tomography and in vitro study.
Bankstahl JP; Bankstahl M; Römermann K; Wanek T; Stanek J; Windhorst AD; Fedrowitz M; Erker T; Müller M; Löscher W; Langer O; Kuntner C
Drug Metab Dispos; 2013 Apr; 41(4):754-62. PubMed ID: 23305710
[TBL] [Abstract][Full Text] [Related]
4. (18)F-FCWAY, a serotonin 1A receptor radioligand, is a substrate for efflux transport at the human blood-brain barrier.
Liow JS; Zoghbi SS; Hu S; Hall MD; Hines CS; Shetty HU; Araneta MD; Page EM; Pike VW; Kreisl WC; Herscovitch P; Gottesman MM; Theodore WH; Innis RB
Neuroimage; 2016 Sep; 138():134-140. PubMed ID: 27211474
[TBL] [Abstract][Full Text] [Related]
5. P-Glycoprotein, not BCRP, Limits the Brain Uptake of [(18)F]Mefway in Rodent Brain.
Choi JY; Song JS; Lee M; Cho WK; Chung J; Lyoo CH; Kim CH; Park J; Lee KC; Kim KM; Kang JH; Bae MA; Ryu YH
Mol Imaging Biol; 2016 Apr; 18(2):267-73. PubMed ID: 26250653
[TBL] [Abstract][Full Text] [Related]
6. Dissimilar Effect of P-Glycoprotein and Breast Cancer Resistance Protein Inhibition on the Distribution of Erlotinib to the Retina and Brain in Humans and Mice.
Biali ME; Auvity S; Cisternino S; Smirnova M; Hacker M; Zeitlinger M; Mairinger S; Tournier N; Bauer M; Langer O
Mol Pharm; 2023 Nov; 20(11):5877-5887. PubMed ID: 37883694
[TBL] [Abstract][Full Text] [Related]
7. A novel PET protocol for visualization of breast cancer resistance protein function at the blood-brain barrier.
Wanek T; Kuntner C; Bankstahl JP; Mairinger S; Bankstahl M; Stanek J; Sauberer M; Filip T; Erker T; Müller M; Löscher W; Langer O
J Cereb Blood Flow Metab; 2012 Nov; 32(11):2002-11. PubMed ID: 22828996
[TBL] [Abstract][Full Text] [Related]
8. Impact of P-gp and BCRP on pulmonary drug disposition assessed by PET imaging in rats.
Mairinger S; Hernández-Lozano I; Filip T; Sauberer M; Löbsch M; Stanek J; Wanek T; Sake JA; Pekar T; Ehrhardt C; Langer O
J Control Release; 2022 Sep; 349():109-117. PubMed ID: 35798092
[TBL] [Abstract][Full Text] [Related]
9. Role of Human Breast Cancer Related Protein versus P-Glycoprotein as an Efflux Transporter for Benzylpenicillin: Potential Importance at the Blood-Brain Barrier.
Li Y; Wu Q; Li C; Liu L; Du K; Shen J; Wu Y; Zhao X; Zhao M; Bao L; Gao J; Keep RF; Xiang J
PLoS One; 2016; 11(6):e0157576. PubMed ID: 27300692
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and in vivo evaluation of [11C]tariquidar, a positron emission tomography radiotracer based on a third-generation P-glycoprotein inhibitor.
Bauer F; Kuntner C; Bankstahl JP; Wanek T; Bankstahl M; Stanek J; Mairinger S; Dörner B; Löscher W; Müller M; Erker T; Langer O
Bioorg Med Chem; 2010 Aug; 18(15):5489-97. PubMed ID: 20621487
[TBL] [Abstract][Full Text] [Related]
11. Saturable active efflux by p-glycoprotein and breast cancer resistance protein at the blood-brain barrier leads to nonlinear distribution of elacridar to the central nervous system.
Sane R; Agarwal S; Mittapalli RK; Elmquist WF
J Pharmacol Exp Ther; 2013 Apr; 345(1):111-24. PubMed ID: 23397054
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and in vivo evaluation of the putative breast cancer resistance protein inhibitor [11C]methyl 4-((4-(2-(6,7-dimethoxy-1,2,3,4-tetrahydroisoquinolin-2-yl)ethyl)phenyl)amino-carbonyl)-2-(quinoline-2-carbonylamino)benzoate.
Mairinger S; Langer O; Kuntner C; Wanek T; Bankstahl JP; Bankstahl M; Stanek J; Dörner B; Bauer F; Baumgartner C; Löscher W; Erker T; Müller M
Nucl Med Biol; 2010 Jul; 37(5):637-44. PubMed ID: 20610168
[TBL] [Abstract][Full Text] [Related]
13. Brain distribution of cediranib is limited by active efflux at the blood-brain barrier.
Wang T; Agarwal S; Elmquist WF
J Pharmacol Exp Ther; 2012 May; 341(2):386-95. PubMed ID: 22323823
[TBL] [Abstract][Full Text] [Related]
14. Quantitative proteomics of transporter expression in brain capillary endothelial cells isolated from P-glycoprotein (P-gp), breast cancer resistance protein (Bcrp), and P-gp/Bcrp knockout mice.
Agarwal S; Uchida Y; Mittapalli RK; Sane R; Terasaki T; Elmquist WF
Drug Metab Dispos; 2012 Jun; 40(6):1164-9. PubMed ID: 22401960
[TBL] [Abstract][Full Text] [Related]
15. Interaction of HM30181 with P-glycoprotein at the murine blood-brain barrier assessed with positron emission tomography.
Bauer F; Wanek T; Mairinger S; Stanek J; Sauberer M; Kuntner C; Parveen Z; Chiba P; Müller M; Langer O; Erker T
Eur J Pharmacol; 2012 Dec; 696(1-3):18-27. PubMed ID: 23022332
[TBL] [Abstract][Full Text] [Related]
16. P-glycoprotein and breast cancer resistance protein affect disposition of tandutinib, a tyrosine kinase inhibitor.
Yang JJ; Milton MN; Yu S; Liao M; Liu N; Wu JT; Gan L; Balani SK; Lee FW; Prakash S; Xia CQ
Drug Metab Lett; 2010 Dec; 4(4):201-12. PubMed ID: 20670210
[TBL] [Abstract][Full Text] [Related]
17. Impact of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) on the brain distribution of a novel BRAF inhibitor: vemurafenib (PLX4032).
Mittapalli RK; Vaidhyanathan S; Sane R; Elmquist WF
J Pharmacol Exp Ther; 2012 Jul; 342(1):33-40. PubMed ID: 22454535
[TBL] [Abstract][Full Text] [Related]
18. Functional Evaluation of P-gp and Bcrp at the Murine Blood-Cerebrospinal Fluid Barrier.
Sun A; Wang J
Pharm Res; 2023 Nov; 40(11):2667-2675. PubMed ID: 37704894
[TBL] [Abstract][Full Text] [Related]
19. Co-administration strategy to enhance brain accumulation of vandetanib by modulating P-glycoprotein (P-gp/Abcb1) and breast cancer resistance protein (Bcrp1/Abcg2) mediated efflux with m-TOR inhibitors.
Minocha M; Khurana V; Qin B; Pal D; Mitra AK
Int J Pharm; 2012 Sep; 434(1-2):306-14. PubMed ID: 22633931
[TBL] [Abstract][Full Text] [Related]
20. Astragali radix and its main bioactive compounds activate the Nrf2-mediated signaling pathway to induce P-glycoprotein and breast cancer resistance protein.
Lou Y; Guo Z; Zhu Y; Zhang G; Wang Y; Qi X; Lu L; Liu Z; Wu J
J Ethnopharmacol; 2019 Jan; 228():82-91. PubMed ID: 30243825
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
